Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells

被引:19
作者
Vad-Nielsen, Johan [1 ]
Gammelgaard, Kristine Raaby [1 ]
Daugaard, Tina Fuglsang [1 ]
Nielsen, Anders Lade [1 ]
机构
[1] Aarhus Univ, Dept Biomed, DK-8000 Aarhus C, Denmark
关键词
NSCLC; EMT; CRISPR-dCAS9; EGFR; FGFR1; ZEB1; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; DRUG-RESISTANCE; TKI RESISTANCE; GROWTH; ACTIVATION; MECHANISMS; MUTATIONS; GEFITINIB; EMT;
D O I
10.1016/j.lungcan.2019.04.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Increased FGFR1 expression is associated with resistance to tyrosine kinase inhibitors (TKIs) in EGFR-mutated NSCLC cells and often concomitant with epithelial to mesenchymal transition (EMT). However, the cause-and-effect relationship between increased FGFR1 expression and EMT in the genetic background of EGFR-mutated non-small cell lung cancer (NSCLC) cells is not clear. Previous studies have specifically addressed the relationship between EMT and increased FGFR1 expression in the context of simultaneous TKI-mediated blocking of EGFR-signaling. Here, in the context of EGFR-mutated NSCLC cells with active EGFR-signaling, we have examined whether increased FGFR1 expression drives EMT or is an EMT passenger event. Materials and methods: For cause-and-effect analyses between EMT and FGFR1 expression, including expression of alternative spliced FGFR1 isoforms, we used CRISPR-dCAS9-SAM-mediated induction of the endogenous FGFRI and ZEB1 genes, as well as biochemical EMT-induction, in PC9 and HCC827 NSCLC cell lines harboring activating EGFR-mutations. Results: We find that FGFR1 expression correlates with a ZEB1-associated EMT gene expression profile in NSCLC cells. In experiments using NSCLC cell lines harboring activating EGFR-mutations we show that CRISPR-dCAS9-SAM-mediated induction of FGFRI expression is neither driving an increase in ZEB1 expression nor EMT characteristics. However, CRISPR-dCAS9-SAM-mediated induction of ZEB1 expression drives EMT characteristics and an increase in FGFRI expression. Biochemical induction of EMT also drives an increase in FGFR1 expression. Conclusion From our findings concerning the cause-and-effect relationship in the genetic background of EGFR-mutated NSCLC cells, we conclude that an increase in ZEBI expression is a driver of EMT resulting in concomitant increased FGFRI expression, whereas an increase in FGFRI expression is insufficient to drive concomitant EMT.
引用
收藏
页码:132 / 140
页数:9
相关论文
共 58 条
[1]   Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition [J].
Acevedo, Victor D. ;
Gangula, Rama D. ;
Freeman, Kevin W. ;
Li, Rile ;
Zhang, Youngyou ;
Wang, Fen ;
Ayala, Gustavo E. ;
Peterson, Leif E. ;
Ittmann, Michael ;
Spencer, David M. .
CANCER CELL, 2007, 12 (06) :559-571
[2]   EMT: 2016 [J].
Angela Nieto, M. ;
Huang, Ruby Yun-Ju ;
Jackson, Rebecca A. ;
Thiery, Jean Paul .
CELL, 2016, 166 (01) :21-45
[3]  
[Anonymous], SCI REP UK
[4]   Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer [J].
Arumugam, Thiruvengadam ;
Ramachandran, Vijaya ;
Fournier, Keith F. ;
Wang, Huamin ;
Marquis, Lauren ;
Abbruzzese, James L. ;
Gallick, Gary E. ;
Logsdon, Craig D. ;
McConkey, David J. ;
Choi, Woonyoung .
CANCER RESEARCH, 2009, 69 (14) :5820-5828
[5]   FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor [J].
Azuma, Koichi ;
Kawahara, Akihiko ;
Sonoda, Kahori ;
Nakashima, Kazutaka ;
Tashiro, Kousuke ;
Watari, Kosuke ;
Izumi, Hiroto ;
Kage, Masayoshi ;
Kuwano, Michihiko ;
Ono, Mayumi ;
Hoshino, Tomoaki .
ONCOTARGET, 2014, 5 (15) :5908-5919
[6]   A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition [J].
Bracken, Cameron P. ;
Gregory, Philip A. ;
Kolesnikoff, Natasha ;
Bert, Andrew G. ;
Wang, Jun ;
Shannon, M. Frances ;
Goodall, Gregory J. .
CANCER RESEARCH, 2008, 68 (19) :7846-7854
[7]   Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer [J].
Brown, Wells S. ;
Tan, Li ;
Smith, Andrew ;
Gray, Nathanael S. ;
Wendt, Michael K. .
MOLECULAR CANCER THERAPEUTICS, 2016, 15 (09) :2096-2106
[8]  
CHAE Y, 2018, SCI REP UK, V8
[9]   Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application [J].
Chae, Young Kwang ;
Ranganath, Keerthi ;
Hammerman, Peter S. ;
Vaklavas, Christos ;
Mohindra, Nisha ;
Kalyan, Aparna ;
Matsangou, Maria ;
Costa, Ricardo ;
Carneiro, Benedito ;
Villaflor, Victoria M. ;
Cristofanilli, Massimo ;
Giles, Francis J. .
ONCOTARGET, 2017, 8 (09) :16052-16074
[10]   Regulatory networks defining EMT during cancer initiation and progression [J].
De Craene, Bram ;
Berx, Geert .
NATURE REVIEWS CANCER, 2013, 13 (02) :97-110